Exscientia, the Medical University of Vienna and the CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences has published final results from the EXALT-1 trial in Cancer Discovery. The study, titled “Functional Precision Medicine Provides Clinical Benefit in Advanced Aggressive Haematological Cancers and Identifies Exceptional Responders,” illustrates the potential… Read More
Many small molecule inhibitors have been approved as cancer therapeutics, but they can confer mutation-based drug resistance and many potential cancer targets remain ‘undruggable’. One emerging cancer therapeutic strategy that shows promise for drug development is the use of targeted protein degradation (TPD). This approach has many advantages,… Read More
Scientists revealed in a new study how gut bacteria contribute to the progression of advanced prostate cancers and their resistance to hormone therapy by providing an alternative source of growth-promoting androgens, or male hormones. Hormone therapy is the standard of care for advanced prostate cancer and works… Read More
Crown Bioscience has launched its ‘3D Ex Vivo Patient Tissue Platform’ which, using freshly collected patient tumour material, can accurately measure oncology and immuno-oncology drug-induced tumour killing and endogenous immune cell proliferation in a high throughput format. Researchers presented data on the new platform at 2021’s AACR-NCI-EORTC International Conference on Molecular Targets and… Read More
Challenges and Opportunities in Protein Degradation, is free webinar hosted by DDW and supported by Cell Signaling Technology (CST). It took place on 21 October, 2021 and is now available to watch on demand for free here. Dr. Nathanael Gray, Professor of… Read More
News round-up by DDW’s Megan Thomas for 4-8 October For this week’s drug discovery round up, DDW’s Megan Thomas focuses on stories that provide answers to previously unanswered questions, or news that enables researchers and scientists to find those answers quickly. 1. Novel therapy could… Read More
Advances in treatments for human diseases, including cancer, rely on the ability to gain detailed information into the function, modulation, and variation of the immune system in response to stimuli or immunological challenge. Insights derived from these data have, for example, revolutionised cancer treatment by enabling the development of… Read More
GammaDelta Therapeutics has initiated a first-in-human Phase I clinical trial evaluating GDX012 for the treatment of acute myeloid leukaemia (AML). GDX012 is an allogeneic, non-engineered, variable delta 1 (Vδ1) gamma-delta (γδ) T cell therapy manufactured from healthy donor blood. AML is the most common form of acute leukaemia in adults with an… Read More
In this free webinar, supported by Cell Signaling Technology (CST) and hosted by DDW, Dr. Nathanael Gray, Professor of Chemical and Systems Biology at the Stanford Cancer Institute, will discuss an emerging strategy for cancer therapeutic development – targeted protein degradation (TPD). Challenges and Opportunities in Protein Degradation, took place on… Read More
Mount Sinai researchers have developed a therapy that shows promise against a fatal paediatric leukaemia. The small-molecule therapy was highly effective in fighting a type of acute myeloid leukaemia in both in vitro and in vivo experiments, according to research published in Science Translational Medicine in September 2021. The therapy, named MS67, causes… Read More
Researchers have discovered a potential advancement in the treatment of chronic myeloid leukaemia (CML), which they hope will one day offer an improved option for treating patients with this form of blood cancer. The study– published in Science Translational Medicine and led by the University of Glasgow in collaboration with… Read More
September 2021 has been Cancer Awareness Month for Blood, Childhood, Gynaecologic, Ovarian and Prostate Cancer, which affect millions of people around the world annually. Here is a round-up of eight of some of the innovative research and studies being done in order to tackle these various types of cancer. … Read More
A large, international collaboration led by researchers from the Johns Hopkins Kimmel Cancer Center has identified promising new targets for pancreatic cancer treatment and early diagnosis after examining various aspects of these tumours’ genes and proteins. “Right now, patients with pancreatic cancer have very few options, and the wealth… Read More
News round-up by DDW’s Megan Thomas for 20-24 September September is Cancer Awareness Month, so this week DDW’s Megan Thomas has rounded up her top five news stories which showcase the work and research of scientists in the fight against cancer. AstraZeneca Imfinzi combination effective… Read More
A new combination of targeted drugs for a type of ovarian cancer has shown promising results in an early clinical trial, shrinking tumours in half of patients. The combination of drugs, which both work by blocking signals cancer cells need to grow, could offer a new treatment option for women with… Read More
Results from a Phase III trial show promise for patients with advanced breast cancer. Enhertu has been shown to reduce the risk of disease progression or death by 72% vs. trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer. Phase III head-to-head DESTINY-Breast03 results featured at ESMO… Read More
